New Risk • May 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.6m free cash flow). Revenue is less than US$1m. Market cap is less than US$10m (US$4.51m market cap). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). Announcement • Apr 04
Matinas BioPharma Holdings, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards On April 2, 2026, Matinas BioPharma Holdings, Inc. (the Company) received a written notice (the Notice) from the NYSE American LLC (the NYSE American) indicating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the Company Guide) requiring a company to have stockholders' equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring a company to have stockholders' equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years and Section 1003(a)(iii) of the Company Guide requiring a company to have stockholders' equity of at least $6.0 million if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years. As of December 31, 2025, the Company had stockholders' equity of $4.83 million and has had losses in the most recent five fiscal years ended December 31, 2025. The Notice also indicates that the Company is not currently eligible for any exemption in Section 1003(a) of the Company Guide. The Company is now subject to the procedures and requirements of Section 1009 of the Company Guide. The Company has until May 2, 2026 to submit a plan (the Plan) of actions it has taken or will take to regain compliance with the continued listing standards and may be eligible for up to 18 months from receipt of the Notice (Cure Period) to regain compliance. The Company intends to submit the Plan to regain compliance with NYSE American listing standards. However, there can be no assurance that the Company will be able to achieve compliance with such standards within the Cure Period. If the NYSE American accepts the Plan, the Company will be able to continue its listing during the Cure Period and will be subject to periodic reviews including quarterly monitoring for compliance with the Plan until it has regained compliance. If the Plan is not accepted by the NYSE American, the Notice states that delisting proceedings will commence. The Company may appeal a staff delisting determination in accordance with Section 1010 and Part 12 of the Company Guide. The Notice has no immediate impact on the listing of the Company's shares of common stock, which will continue to be listed and traded on the NYSE American, subject to the Company's compliance with the other listing requirements of the NYSE American. The Notice does not affect the Company's ongoing business operations or its reporting requirements with the Securities and Exchange Commission. Announcement • Jan 24
Matinas Biopharma Holdings, Inc. Appoints Jerome D. Jabbour as Interim Chief Financial Officer, Effective January 22, 2026 On January 22, 2026, the board of directors of Matinas BioPharma Holdings, Inc. appointed Jerome D. Jabbour, the Company’s current Chairman of the Board, President and Chief Executive Officer, as the Company’s interim Chief Financial Officer, effective January 22, 2026. Mr. Jabbour will continue in his roles as Chairman of the Board, President and Chief Executive Officer and will assume the duties of the Company's principal financial officer and principal accounting officer until his successor is appointed or until his earlier resignation or removal. Mr. Jabbour, 51, was appointed as the Company's Chief Executive Officer in March 2018 and was named Chairman of the Board in March 2025. He has served as the Company's President since March 2016. Prior to that, he served as the Company's Executive Vice President, Chief Business Officer, General Counsel and Secretary beginning in October 2013 and as a member of the Board from April 2012 until November 2013. Mr. Jabbour is also a co-founder of the Company. Prior to joining the Company, he was the Executive Vice President and General Counsel of MediMedia USA from 2012 to October 2013. Prior to MediMedia, he was the Senior Vice President and Head of Global Legal Affairs of Wockhardt Limited from 2008 to 2012, and Senior Counsel and Assistant Secretary at Reliant from 2004 to 2008. Earlier in his career, he held positions as Commercial Counsel at Alpharma, Inc. from 2003 to 2004 and as a Corporate Associate at Lowenstein Sandler LLP from 1999 to 2003. Mr. Jabbour earned his J.D. from Seton Hall University School of Law in New Jersey and a B.A. in Psychology from Loyola University in Baltimore. 
